Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07102342 · ClinicalTrials.gov registry record · Phase 1
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
A Phase 1 study of Parkinson Disease, sponsored by iRegene Therapeutics Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT07102342: Recruiting Phase 1 study of Parkinson Disease, sponsored by iRegene Therapeutics Co..
NCT07102342 is a Phase 1 study of Parkinson Disease that is actively recruiting participants, run by iRegene Therapeutics Co.. The registered enrollment target is 5 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07102342, a Phase 1 study of Parkinson Disease, is actively recruiting participants, sponsored by iRegene Therapeutics Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.
Primary Outcome
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
Conditions Studied
Interventions
- BIOLOGICAL Human Dopaminergic Progenitor Cells
Study Locations (1)
New York
- Cornell University Weill Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2026-01-12 |
| Est. Completion | 2032-09 |
| Phase | Phase 1 |
What NCT07102342 shows while recruiting
NCT07102342 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Human Dopaminergic Progenitor Cells is the first listed.
NCT07102342 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07102342 about?
NCT07102342 is a clinical study titled "This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.". This is a phase 1 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.
What is the current status of trial NCT07102342?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2026-01-12. Estimated completion is 2032-09.
What conditions does trial NCT07102342 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT07102342?
The interventions under investigation include: Human Dopaminergic Progenitor Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT07102342?
This trial is sponsored by iRegene Therapeutics Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07102342 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07102342's enrollment target sits among peer trials
5 292nd of 297 higher than 5 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
RECRUITING · Phase 1
-
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI